- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Remiges Ventures
BioCentury | Apr 18, 2025
Finance
New fund Alis offers struggling biotechs an off-ramp: Finance Report
Plus: Updates from Glycomine, Attovia, Thirtyfivebio, Heparegenix, Duality, Pelthos and Third Harmonic
BioCentury | Apr 23, 2024
Deals
Deals report: Two Japanese pharmas set up local biotech incubator
Plus: Takeda licenses immuno-oncology program from Kumquat, and deals for Ipsen-Skyhawk, Boehringer-Ochre and more
BioCentury | Apr 7, 2023
Regulation
April 6 Quick Takes: Makena pulled from market
Plus: Takeda ending early AAV gene therapy, rare hematology work and updates from Pharmakon, Capacity Bio
BioCentury | Jun 7, 2022
Emerging Company Profile
LUCA: off-the-shelf mitochondria for wide-ranging applications
Tokyo-based LUCA believes mitochondrial transplant can restore function after heart attack, treat rare diseases, enhance cell therapies and more
BioCentury | Jun 24, 2021
Finance
Funding roundup: F-Prime leads series A for Toronto Dx company Adela; plus fresh funding for Strand, Tvardi, Orum, Glycomine and HutchMed
Meanwhile, digital biotech Pear readies for SPAC
BioCentury | Apr 8, 2021
Finance
With $95M second fund and incubator, Japan-focused Remiges helps start-ups take flight
Cross-border firm to launch newcos out of Japanese academia
BioCentury | Jul 10, 2020
Finance
$30M series A will propel Tranquis to the clinic with its neuroinflammation candidate
BioCentury | Aug 30, 2019
Financial News
Aug. 30 Financial Quick Takes: Remiges launches second fund with $30M from Taiho; ERADA gets grant for malaria diagnostic
BioCentury | Oct 19, 2018
Finance
Taiho ups its stakes
Taiho Ventures’ upsized fund will enable the venture arm to take larger stakes
BioCentury | Jan 19, 2018
Strategy
After amyloid
How the Alzheimer’s disease community is moving past amyloid
Items per page:
1 - 10 of 22